Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston starts spine stimulation study

This article was originally published in Clinica

Executive Summary

Boston Scientific has kicked off a study of its Precision Plus spinal cord stimulator system. The randomised, controlled EVIDENCE trial will enrol 132 patients who had previously undergone spinal surgery which had failed to alleviate persistent back and leg pain. The study will compare the therapeutic efficacy and cost-effectiveness of spinal cord stimulation (SCS) therapy using the Precision Plus system with spine reoperation. The rates of leg pain relief with no request for the alternative therapy with both strategies will be compared at six and 24 months. The Precision Plus delivers electrical signals via the spinal cord to the brain. These pulses change pain signals into signals that the brain interprets as a pleasant sensation. It is indicated for aiding the management of chronic pain in the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery and intractable lower back and leg pain.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel